课题基金 / 基金详情

PATHOGENESIS OF INTESTINAL DYSFUNCTION IN SIMIAN AIDS

PATHOGENESIS OF INTESTINAL DYSFUNCTION IN SIMIAN AIDS
猿猴艾滋病肠功能障碍的发病机制
批准号:
7349660
负责人:
Satya Dandekar
金额:
$15.67万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-05-01 至 2007-04-30

项目摘要

项目成果

Satya Dandekar的其他基金

相似基金

相关文献

中文摘要
翻译
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得主要资金,因此可以在其他CRISP条目中表示。所列机构为中心,不一定是研究者所在机构。目的:猿猴免疫缺陷病毒(SIV)和人类免疫缺陷病毒(HIV)感染导致肠道相关淋巴组织(GALT)中的CD 4 T细胞快速耗竭。虽然抗逆转录病毒治疗(ART)的管理已被证明可以增加外周血中的CD 4 T细胞水平在SIV和HIV感染,其在恢复肠粘膜CD 4 T细胞的疗效还没有得到很好的研究。为了深入了解病毒诱导的粘膜免疫系统破坏的分子机制,我们评估了在SIV感染的恒河猴中,在ART存在或不存在的情况下,病毒负荷、T细胞亚群和粘膜基因表达谱的纵向变化。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: Simian immunodeficiency virus (SIV) and human immunodeficiency virus (HIV) infections lead to rapid depletion of CD4 T cells from gut-associated lymphoid tissue (GALT). Although the administration of antiretroviral therapy (ART) has been shown to increase CD4 T-cell levels in the peripheral blood in both SIV and HIV infections, its efficacy in restoring intestinal mucosal CD4 T cells has not been well investigated. To gain insights into the molecular mechanisms of virally induced disruptions in the mucosal immune system, we have evaluated longitudinal changes in viral burden, T-cell subsets, and mucosal gene expression profiles in SIV-infected rhesus macaques in the absence or presence of ART.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecules and Pathways at the Coccidioides Host-Pathogen Interface
Immune and metabolic correlates of Coccidioides disease spectrum and outcomes
Immune and metabolic correlates of Coccidioides disease spectrum and outcomes
Molecules and Pathways at the Coccidioides Host-Pathogen Interface
海外基金